<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734744</url>
  </required_header>
  <id_info>
    <org_study_id>HS-18-00737</org_study_id>
    <nct_id>NCT03734744</nct_id>
  </id_info>
  <brief_title>PK/PD of Vitamin D3 in Adults With CF</brief_title>
  <official_title>A Pilot Study Evaluating Single, High-dose Pharmacokinetics/Pharmacodynamics of Vitamin D3 in CF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the extensive literature on adverse clinical outcomes associated with vitamin D
      deficiency, there are currently no proven treatment strategy that effectively achieves and
      maintains optimal serum vitamin D status in cystic fibrosis (CF) patients. For the treatment
      of vitamin D deficiency, CF Foundation currently recommends 2,000 IU daily. However, because
      achieving adequate serum 25(OH)D levels is a challenge in CF, higher doses of vitamin D may
      be necessary to reach and maintain vitamin D sufficiency. Poor oral bioavailability of
      ergocalciferol has been demonstrated in CF patients, which may potentially also be an issue
      with cholecalciferol. In order to optimize the treatment of vitamin D deficiency in CF, the
      kinetic disposition must be well understood. However, there are very few data currently
      available describing the kinetics of both vitamin D and 25-hydroxyvitamin D, and to the
      investigator's knowledge, no studies have yet characterized the pharmacokinetic disposition
      of vitamin D and its metabolites in cystic fibrosis. Addressing this issue is crucial in
      effectively and safely correcting vitamin D deficiency in CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinically stable CF patients with a history of pancreatic insufficiency (n=6) and matching
      non-CF subjects (n=6) will be recruited in this study. All subjects will be pre-screened for
      25(OH)D status to include those with 25(OH)D levels below 30 ng/mL. The subjects will receive
      a single oral dose (300,000 - 600,000 IU) of vitamin D3, and the dose will be based on study
      participant's baseline 25-hydroxyvitamin D3 level. For CF patients, the dose will be
      administered with food and pancreatic enzyme supplement. This dose was chosen as previous
      studies in pediatric CF patients demonstrated that a large single dose of up to 600,000 IU
      vitamin D3 raised and maintained sufficient 25(OH)D concentrations without any signs of
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentrations (Cmax)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach the maximum concentration (Tmax)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of serum inflammatory biomarkers</measure>
    <time_frame>10 weeks</time_frame>
    <description>Changes in IL-6, IL-8, TNF-α, IL-1β, C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Adults with Cystic Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CF Controls with Low vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health</description>
    <arm_group_label>Adults with Cystic Fibrosis</arm_group_label>
    <arm_group_label>Non-CF Controls with Low vitamin D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For CF, diagnosis of CF based on positive sweat chloride or known CF mutation

          -  For CF, Patients with pancreatic insufficiency

          -  Age ≥ 18 years

          -  Serum 25(OH)D concentrations below 30 ng/mL (75 nmol/L)

        Exclusion Criteria:

          -  Pregnancy

          -  History of lung transplant,

          -  Severe anemia (hemoglobin concentration &lt; 7 g/dL),

          -  Liver disease (AST/ALT &gt; 3x ULN), kidney disease (GFR ≤ 40 mL/min), or granulomatous
             conditions

          -  Patients taking steroids, cholesterol-lowering drug (cholestyramine), weight-loss
             drugs (orlistat) , statins, anti-tuberculosis drugs (rifampin and isoniazid),
             phenobarbital, phenytoin, carbamazepine, immunosuppressants (cyclosporine, tacrolimus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M Beringer, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul M Beringer, Pharm.D.</last_name>
    <phone>323-442-1402</phone>
    <email>beringer@usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keck Hospital of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Fukushima, RN</last_name>
      <phone>323-442-5869</phone>
      <email>lynn.fukushima@med.usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011 Jan;86(1):50-60. doi: 10.4065/mcp.2010.0567. Review.</citation>
    <PMID>21193656</PMID>
  </reference>
  <reference>
    <citation>Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D; Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012 Apr;97(4):1082-93. doi: 10.1210/jc.2011-3050. Epub 2012 Mar 7.</citation>
    <PMID>22399505</PMID>
  </reference>
  <reference>
    <citation>Shepherd D, Belessis Y, Katz T, Morton J, Field P, Jaffe A. Single high-dose oral vitamin D3 (stoss) therapy--a solution to vitamin D deficiency in children with cystic fibrosis? J Cyst Fibros. 2013 Mar;12(2):177-82. doi: 10.1016/j.jcf.2012.08.007. Epub 2012 Sep 19.</citation>
    <PMID>22998937</PMID>
  </reference>
  <reference>
    <citation>Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012 Apr 1;4(2):191-7. doi: 10.4161/derm.20332.</citation>
    <PMID>22928076</PMID>
  </reference>
  <reference>
    <citation>Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler MM, Aris RM. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr. 2001 Mar;73(3):602-6.</citation>
    <PMID>11237938</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Beringer</investigator_full_name>
    <investigator_title>Professor of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03734744/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

